Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
ID: 356341Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356341

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-043.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for research investigating the mechanisms by which bariatric surgery impacts cancer risk, under the title "Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)." This initiative aims to support studies that explore the long-term effects of bariatric surgery on cancer risk, moving beyond immediate outcomes such as weight loss and diabetes, and considering factors like sex, racial background, and procedure type. With a funding ceiling of $500,000 per year for up to five years, the program encourages innovative research proposals from a diverse range of eligible applicants, including educational institutions and community organizations. Applications are due by January 7, 2028, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-043.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-043.html
    The Department of Health and Human Services is offering funding opportunities through the National Institutes of Health (NIH) for research that investigates mechanisms by which bariatric surgery affects cancer risk. This initiative focuses on studies beyond immediate outcomes like weight loss, delving into how bariatric procedures potentially influence various cancer risks. Applications are invited from diverse entities, including educational institutions and nonprofits, with a project budget capped at $500,000 per year for a maximum of five years. The program specifically seeks to understand how factors such as sex, racial background, and procedure type may alter cancer risk across different patient populations. Researchers are encouraged to employ both animal and human models in their investigations, with proposals due starting January 5, 2025. The funding aims to further elucidate the biological mechanisms at play in the cancer risk landscape following bariatric surgery, addressing pressing public health challenges, particularly as obesity-related deaths are rapidly rising. The NIH outlines clear application and eligibility requirements, emphasizing the importance of innovation and scientific rigor in the research proposals submitted. Overall, this funding opportunity represents a significant investment in understanding the complex interplay between obesity, surgery, and cancer prevention.
    Similar Opportunities
    Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)." This grant aims to support innovative, investigator-initiated studies that explore how bariatric surgery influences cancer risk, moving beyond traditional short-term outcomes such as weight loss and diabetes management. Given the rising prevalence of obesity and the increasing number of bariatric surgeries performed in the U.S., this research is crucial for identifying new pathways for cancer prevention. The grant provides funding of up to $275,000 over two years, with applications due by January 16, 2025, and additional cycles available through 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-044.html.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 exploratory research grant titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics." This grant aims to support preclinical and patient-based studies that investigate how incretin mimetics, specifically GLP-1 and GIP-1 receptor agonists, influence cancer risk, particularly in relation to obesity-related cancers such as thyroid and prostate cancers. The funding, which amounts to a maximum of $275,000 over two years, is intended for projects that do not involve clinical trials, with applications opening in January 2024 and a submission deadline of January 7, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)" aimed at promoting research into the effects of incretin mimetics on cancer risk. This initiative seeks to support preclinical and patient-based studies that explore the mechanisms by which these agents, including GLP-1 and dual GLP-1/GIP-1 receptor agonists, may influence cancer risk, particularly in relation to obesity-related cancers. The funding is available to a wide range of eligible applicants, including various educational institutions and organizations, with no cost-sharing requirement, and projects can span up to five years. Interested applicants should note that the application deadline is January 7, 2027, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-069.html.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)" aimed at investigating how incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk. The program seeks to promote preclinical and patient-based studies that explore the mechanisms by which these agents affect cancer, especially in relation to obesity-related cancers, while attracting talented scientists to focus on long-term outcomes rather than short-term effects like weight loss and diabetes. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with applications encouraged to begin submission starting January 5, 2024, for projects with a funding period of up to five years. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and the opportunity is set to close on January 7, 2027.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)." This initiative aims to promote exploratory research into the biological mechanisms by which incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk, with a focus on understanding their effects beyond diabetes treatment. The funding, which amounts to a maximum of $275,000 over two years, is intended to attract diverse researchers and institutions to fill significant gaps in current cancer biology research. Interested applicants should note that the application submission period begins on January 16, 2025, and can find further details and guidelines at the NIH grants website or by contacting NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity (PAR-23-051) aimed at investigating the mechanistic links between diet, lipid metabolism, and tumor growth and progression. This initiative seeks applications that explore how dietary patterns, particularly high-fat or ketogenic diets, influence cancer cell metabolism and tumor behavior, with a focus on the role of lipids in these processes. The program is designed to bridge the fields of nutrition and molecular metabolism, stimulate research, and develop tools to enhance understanding in this area, while emphasizing collaboration among investigators with expertise in nutrition. Applicants may request up to $500,000 annually for a maximum of five years, with the application deadline set for October 23, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)" aimed at exploring the connections between dietary factors and cancer biology. This initiative seeks applications that investigate the molecular mechanisms linking lipid metabolism to tumor growth and progression, with a particular focus on how dietary lipids influence the tumor microenvironment and associated health disparities. The program supports exploratory research with a maximum funding request of $275,000 in direct costs over two years, and applications are due by October 23, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-118.html.
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)" aimed at advancing research in the intersection of nutrition and cancer biology. This initiative seeks applications that investigate the molecular mechanisms by which lipid metabolism influences tumor dynamics, particularly focusing on the effects of dietary lipids and their interactions with the tumor microenvironment. The program is designed to bridge the fields of nutrition and cancer research, with a budget cap of $500,000 per year for up to five years, encouraging innovative studies, especially those involving high-fat or ketogenic diets. Interested applicants can find more information and application guidelines at the provided NIH link, with a submission deadline of October 23, 2025, and inquiries directed to grantsinfo@nih.gov.
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a funding opportunity titled "Mechanistic links between diet, lipid metabolism, and tumor growth and progression," under the UH2 Clinical Trial Not Allowed activity code. This initiative aims to support fundamental studies that investigate the molecular mechanisms linking lipid metabolism to tumor growth, with a focus on bridging the fields of nutrition and molecular metabolism. The program is particularly significant as it addresses critical gaps in understanding the relationship between diet and cancer biology. The funding amount is capped at $275,000 over a two-year period, with applications due by October 23, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (PAR-25-107). This initiative invites grant applications that explore the use of bacteria, archaebacteria, bacteriophages, and non-oncolytic viruses to investigate their interactions with tumors and the immune system, aiming to develop innovative strategies for cancer imaging and therapy, particularly for oral cancers. The program encourages multidisciplinary collaboration among experts in microbiology, cancer biology, and immunology to address challenges associated with solid tumors and metastases. Applications will be accepted starting January 5, 2025, with no budget limit, and the project period can extend up to five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.